2013-03-07 07:07:08 -
Tecan Group AG /
Tecan's OEM partner Dako unveils new platform at global congress
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Männedorf, Switzerland, March 7, 2013 - The Tecan Group (SIX Swiss Exchange:
TECN) announced today that its OEM partner Dako, an Agilent Technologies Company
and worldwide provider of cancer diagnostics, unveiled the new advanced staining
platform at the 2013 USCAP congress in Baltimore, Maryland, USA. Earlier this
week, it was presented to a global gathering of pathologists and lab personnel
for the first time.
In May 2011, Tecan signed a major OEM agreement with Dako for the development
and supply of an advanced staining platform. Formerly the development program
was referred to by Tecan as P16. The solution,
Dako Omnis, comprises hardware,
software and reagents.
Lars Holmkvist, CEO of Dako said: "The Dako Omnis offers full-automation to
satisfy the needs of large-scale laboratories, hospitals and universities. Tecan
has been our ideal development partner for this system due to their strong
application know-how and experience with end-customer workflows in the IHC and
ISH segment. Furthermore, as we progressed through the development, we found
that Tecan shared our values of innovation and ownership and that their
experience in system integration was key in bringing the Dako OMNIS to market."
Tecan CEO David Martyr commented: "We are delighted to work with Dako, a global
leader in the fast growing area of tissue-based cancer diagnostics. The Dako
Omnis is really setting a new standard for advanced staining. We expect sales
volumes for Tecan from the supply of the Dako Omnis to accelerate from the
second half of this year with a substantial contribution to our sales growth
from 2014 onwards. Based on our partnership today, we look forward to further
intensify our relationship with Dako in the future."
Methods used in the diagnosis of abnormal cells such as those found in cancerous
tumors include immunohistochemistry (IHC) and in situ hybridization (ISH). The
Dako Omnis automates both IHC and ISH processes, meaning entire patient cases
can be processed simultaneously. This allows pathologists to make quicker, more
informed diagnoses. Oncologists can in turn prescribe relevant therapy with less
anxiety-ridden waiting time for patients.
With continuous loading, batch loading and overnight run options all available,
Dako Omnis sets new standards for what customers can expect from an automated
platform in terms of flexibility, capacity, efficiency and traceability of
slides. The platform provides state-of-the-art software to bring lab control to
a new level. Now, key processes such as slide processing and instrument
maintenance can be traced to individual operators, greatly increasing quality
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and
solutions in biopharmaceuticals, forensics and clinical diagnostics. The company
specializes in the development, production and distribution of automated
workflow solutions for laboratories in the life sciences sector. Its clients
include pharmaceutical and biotechnology companies, university research
departments, forensic and diagnostic laboratories. As an original equipment
manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM
instruments and components that are then distributed by partner companies.
Founded in Switzerland in 1980, the company has manufacturing, research and
development sites in both Europe and North America and maintains a sales and
service network in 52 countries. In 2012, Tecan generated sales of
CHF 391 million (USD 416 million; EUR 323 million). Registered shares of Tecan
Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Tecan Group AG via Thomson Reuters ONE